2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10449R
    Luseogliflozin (Standard) 898537-18-3 98%
    Luseogliflozin (Standard) is the analytical standard of Luseogliflozin (HY-10449). This product is intended for research and analytical applications. Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes.
    Luseogliflozin (Standard)
  • HY-10451R
    Canagliflozin (Standard) 842133-18-0 99.89%
    Canagliflozin (Standard) is the analytical standard of Canagliflozin. This product is intended for research and analytical applications. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
    Canagliflozin (Standard)
  • HY-10457R
    Velusetrag (Standard) 866933-46-2 98%
    Velusetrag (Standard) is the analytical standard of Velusetrag (HY-10457). This product is intended for research and analytical applications. Velusetrag (TD-5108) is an orally active, potent and selective agonist of serotonin 5-HT4 receptor (5-HT4R), with a pKi of 7.7. Velusetrag exhibits no affinity (Ki>10 μM) for 5-HT2A and 5-HT2B receptors. Velusetrag can be used for the research of gastrointestinal diseases and Parkinson's disease.
    Velusetrag (Standard)
  • HY-10473R
    Eprotirome (Standard) 355129-15-6 98%
    Eprotirome (Standard) is the analytical standard of Eprotirome (HY-10473). This product is intended for research and analytical applications. Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research.
    Eprotirome (Standard)
  • HY-10480R
    Fasiglifam (Standard) 1000413-72-8 98%
    Fasiglifam (Standard) is the analytical standard of Fasiglifam (HY-10480). This product is intended for research and analytical applications. Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 72 nM.
    Fasiglifam (Standard)
  • HY-105047
    Fluorescein lisicol 140616-46-2 98.14%
    Fluorescein lisicol is a fluorescent-labelled bile salt and a marker of hepatic biliary transporter function. Fluorescein lisicol can be used for metabolic research.
    Fluorescein lisicol
  • HY-10512R
    AR-A014418 (Standard) 487021-52-3 98%
    AR-A014418 (Standard) is the analytical standard of AR-A014418. This product is intended for research and analytical applications. AR-A014418 is a potent, selective and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM).
    AR-A014418 (Standard)
  • HY-105217
    Turosteride 137099-09-3 98%
    Turosteride is a selective 5 alpha-reductase inhibitor, with IC50 values of 55 and 53 nM for human and rat prostatic 5 alpha-reductases, respectively. Turosteride can reduce the prostate and seminal vesicle weights.
    Turosteride
  • HY-105900
    Ro 22-0654 81741-99-3 98%
    Ro 22-0654 is a potent lipid synthesis inhibitor. Ro 22-0654 inhibits hepatic fatty acid synthesis and has antiobesity effects.
    Ro 22-0654
  • HY-10595R
    RO-28-1675 (Standard) 300353-13-3
    RO-28-1675 (Standard) is the analytical standard of RO-28-1675 (HY-10595). This product is intended for research and analytical applications. RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC50 of 54 nM. RO-28-1675 can be used for the research of type 2 diabetes.
    RO-28-1675 (Standard)
  • HY-10624R
    THIQ (Standard) 312637-48-2
    THIQ (Standard) is the analytical standard of THIQ (HY-10624). This product is intended for research and analytical applications. THIQ is the first selective agonist of the melanocortin-4 receptor (MC4R), with high affinity and potency for hMC4R (IC50=1.2 nM, EC50=2.1 nM) and rMC4R (IC50=0.6 nM, EC50=2.9 nM). THIQ maintains low potency at MC1R, MC3R and MC5R. THIQ plays a role in eliciting erectile activity in rodents. THIQ acts as a pharmacoperone of the MC4R rescuing the cell surface expression and signaling of some intracellularly retained MC4R mutants.
    THIQ (Standard)
  • HY-106258
    Atilmotin 533927-56-9 98%
    OHM 11638 (Atilmotin), an analogue of the (1-14) fragment of porcine motilin, is a motilin receptor agonist with a pKd of 8.94 for the motilin receptor. OHM 11638 affects esophageal, lower esophageal sphincter (LES), and gastric motility. OHM 11638 increases LES and gastric pressures, OHM 11638 can be used as prokinetic agents.
    Atilmotin
  • HY-10626R
    T0901317 (Standard) 293754-55-9 98%
    T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.
    T0901317 (Standard)
  • HY-106299
    Lilopristone 97747-88-1 98%
    Lilopristone (ZK98734) is a progesterone antagonist with a potential to induce menstruation, inhibit nidation, and terminate pregnancy. Lilopristone blocks progesterone action at the endometrium as well as decreases progesterone bioavailability, and can be utilized in antifertility research.
    Lilopristone
  • HY-10629R
    LXR-623 (Standard) 875787-07-8 98%
    LXR-623 (Standard) is the analytical standard of LXR-623. This product is intended for research and analytical applications. LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.
    LXR-623 (Standard)
  • HY-10794R
    MF498 (Standard) 915191-42-3 98%
    MF498 (Standard) is the analytical standard of MF498 (HY-10794). This product is intended for research and analytical applications. MF498 is a selective and orally active E prostanoid Receptor 4 (EP4) antagonist with a Ki value of 0.7 nM. MF498 can be used in the research of inflammation, such as rheumatoid and osteoarthritis.
    MF498 (Standard)
  • HY-10825R
    DG051 (Standard) 929915-58-2 98%
    DG051 (Standard) is the analytical standard of DG051 (HY-10825). This product is intended for research and analytical applications. DG051 is a potent leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis in the enzyme assay with an IC50=47 nM.
    DG051 (Standard)
  • HY-10871R
    Otenabant (Standard) 686344-29-6
    Otenabant (Standard) is the analytical standard of Otenabant (HY-10871). This product is intended for research and analytical applications. Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.
    Otenabant (Standard)
  • HY-108922
    Probucol disuccinate 216168-45-5 99.14%
    Probucol Disuccinate is a derivative of Probucol (HY-B0388), a lipid-regulating agent and can reduce LDL-cholesterol levels.
    Probucol disuccinate
  • HY-109060
    Garvagliptin 1601479-87-1 98%
    Garvagliptin (ZYDPLA1) is an orally active, competitive and long acting DPP4 Inhibitor, with an IC50 of 2.99 nM against human recombinant DPP IV. Garvagliptin (ZYDPLA1) exhibits antihyperglycemic effect.
    Garvagliptin
Cat. No. Product Name / Synonyms Application Reactivity